Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil Sells 5,000 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a filing with the SEC, which is available through this link.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $111.21 on Wednesday. Jazz Pharmaceuticals plc has a one year low of $103.01 and a one year high of $146.70. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The stock has a market cap of $7.01 billion, a PE ratio of 22.93, a P/E/G ratio of 1.53 and a beta of 0.63. The stock has a 50 day moving average price of $115.56 and a 200 day moving average price of $120.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Equities research analysts expect that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Headlands Technologies LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at $589,000. Concurrent Investment Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at $701,000. Tectonic Advisors LLC raised its position in Jazz Pharmaceuticals by 20.1% in the first quarter. Tectonic Advisors LLC now owns 3,230 shares of the specialty pharmaceutical company’s stock valued at $389,000 after purchasing an additional 540 shares during the period. LSV Asset Management raised its position in Jazz Pharmaceuticals by 1.6% in the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock valued at $286,703,000 after purchasing an additional 37,631 shares during the period. Finally, Envestnet Portfolio Solutions Inc. raised its position in Jazz Pharmaceuticals by 17.1% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 2,418 shares of the specialty pharmaceutical company’s stock valued at $291,000 after purchasing an additional 353 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $222.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, May 2nd. StockNews.com lowered Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Royal Bank of Canada reiterated an “outperform” rating and set a $195.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Piper Sandler increased their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $192.75.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.